The Claim
In mice, the deletion of GLP1 receptors on vagal afferent nerves does not abolish the appetite-suppressing effects of liraglutide, indicating that central nervous system signaling, rather than peripheral vagal signaling, mediates the reduction in food intake.
What the research says
Challenges is higher
Challenge is ahead, but a single strong supporting study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice, removing GLP1 receptors from nerves connecting the gut to the brain does not stop liraglutide from reducing food intake, showing that the brain's direct response to the drug, not signals from the gut, causes the reduction in eating.
See the scientific wording
In mice, GLP1 receptors on vagal afferent nerves are not required for the appetite-suppressing effects of liraglutide, as mice with specific deletion of GLP1R in these nerves showed normal anorectic responses, indicating that central, not peripheral vagal, signaling mediates food intake reduction.
Liraglutide enters the brain and binds to receptors on specific hunger-regulating neurons in the hypothalamus. This directly activates neurons that signal fullness and indirectly turns off neurons that drive hunger, causing a reduction in food intake.
What the research says
1 studyStudy: Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.
The study found that if you remove GLP1 receptors from the brain, liraglutide can’t reduce appetite — but removing them from the gut nerves doesn’t stop it. So the drug works through the brain, not the gut nerves, which actually supports the claim’s conclusion — but the claim wrongly implies the study only tested gut nerves.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.